

MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, March 19, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Lisa Hunt, R.Ph.

Kort Delost, R.Ph.

Elizabeth Young, Pharm.D.

Jameson Rice, Pharm.D.

Roger Martineau, M.D.

Ellie Brownstein, M.D.

Committee Members Excused:

Julia Ozbolt, M.D.

Beth Johnson, R.Ph.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D.

Merelynn Berrett, RN

Trevor Smith, CPhT

Heather Santacruz, RN

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Gary Oderda, UofU

Other Individuals Present:

Sushma Patel, AstraZeneca

Cody Ball, Select Health

Abraham Poulsen, UofU

Kelly Ponce, AstraZeneca

Clinton Sheffield MD, UofU

Paul Bonham, Novo

Meeting conducted by: Kort Delost

1. **Review and Approval of January Minutes:** Because the February P&T meeting was canceled, minutes for January were reviewed. Jameson Rice made a motion to approve the minutes. Beth Young seconded the motion. All in favor.
2. **Housekeeping:**
 - a. Lisa Hunt said that additional States are looking to join the purchasing pool which would increase the purchasing power for potential supplemental rebates.
 - b. Lisa Hunt introduced Dr. Clinton Sheffield. He is visiting as a potential new addition to the P&T committee.
3. **Drug Utilization Review (DUR) Board update:** The DUR board reviewed buprenorphine single agents in the March 2015 meeting. For April, the DUR board is planning to review Botulism toxin treatment and Afrezza.

4. **Diuretic agents (Loop, Potassium Sparing and Thiazide agents)** – The agents were split up to discuss separately with separate motions.
5. **Public Comments:**
 - a. No Public Comment on any agent under discussion.
6. **Thiazide Diuretics:** Melissa Archer presented a review of the Thiazide Diuretic agents. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
7. **Committee discussion:**
 - a. Kort Delost stated that the pediatric patients have a higher chlorothiazide drug utilization.
 - b. Lisa Hunt presented the agents on other State's Preferred Drug Lists.
 - c. Elizabeth Young made a motion that the Thiazide Diuretic agents are equally safe and effective. Roger Martineau seconded the motion. All in favor.
 - d. Ellie Brownstein made a motion to make one liquid agent preferred. Kort Delost seconded the motion. All in favor.
 - e. A question was made about discussing combination agents. Lisa Hunt said that the combination thiazide agents were included in previous classes.
8. **Loop Diuretics:** Melissa Archer presented a review of the Loop Diuretic agents. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
9. **Committee discussion:**
 - a. Kort Delost mentioned that the committee would need to discuss oral and injectable formulations.
 - b. Lisa Hunt presented data from other State's Preferred Drug Lists.
 - c. Jameson Rice said that furosemide is the only Loop Diuretic agent that is available in a liquid formulation.
 - d. Ellie Brownstein made a motion that the Loop Diuretic agents are equally safe and efficacious, but torsemide should be included as a preferred agent. Jameson Rice seconded the motion. All in favor.
 - e. Ellie Brownstein made another motion to make a liquid formulation preferred on the PDL. Roger Martineau seconded the motion. All in favor.
10. **Potassium Sparing Diuretics:** Melissa Archer presented a review of the Potassium Sparing Diuretic agents. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
11. **Committee discussion:**
 - a. Lisa Hunt presented information from other State's PDLs.

- b. The usage of Triamterene as a single agent versus in combination was discussed. The combination is used much more than individually.
 - c. Jameson Rice made a motion saying that the Potassium sparing diuretics are equally safe and efficacious. He added to the motion that because of the high utilization, spironolactone should be included as a preferred agent. Roger Martineau seconded the motion. All in favor.
 - d. Ellie Brownstein made a motion that if a liquid formulation of a potassium sparing diuretic is available, it should be included as a preferred agent. Elizabeth Young seconded the motion. All in favor.
 - e. Kort Delost made a motion that based on utilization, a combination agent, of a potassium sparing diuretic and hydrochlorothiazide should be included as a preferred agent. Elizabeth Young seconded the motion. All in favor.
12. **Meeting Adjourned** – Roger Martineau made a motion to close the meeting. Ellie Brownstein seconded the motion. All in favor. Meeting Adjourned
13. Next meeting is scheduled for April 16, 2015. SGLT-2 agents and the annual training will be discussed.

Minutes prepared by Trevor Smith

Recording available upon request, send email to medicaidpharmacy@utah.gov